Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

NCT00751296 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT00751296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00751296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2006
Completion date
April 30, 2014
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukaemia